multicenter, randomized, double-blind, placebo controlled, parallel group clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion Given as adjunct treatment to oral levOdopa in patients with Parkinson’s Disease with motor fluctuations (iNDiGO)
Public Engagement To determine the effect of two dosing regimens of ND0612 on daily “OFF” time using subjectcompleted
home diary assessments of motor function.